Tag Archives: RANTES (Protein)

Blood Test Potentially Able to Predict Alzheimer’s Disease Onset (BBC News / Alzheimer’s & Dementia)

Posted on July 8, 2014 by Dementia and Elderly Care News

Summary Research published in the Alzheimer’s & Dementia: the Journal of the Alzheimer’s Association may indicate a significant step forwards in developing a blood test which could be able to predict the risk of Alzheimer’s Disease onset with 87% accuracy. Research … Continue reading →

Posted in BBC News, Charitable Bodies, For Doctors (mostly), For Researchers (mostly), In the News, International, Quick Insights, UK, Universal Interest | Tagged A2M (Protein), A2M: Alpha-2-Macroglobulin, Ab40 (Protein), AddNeuroMed Consortium, Alzheimer's Association, Alzheimer's Disease: Diagnosis, Alzheimer’s & Dementia: the Journal of the Alzheimer's Association, Alzheimer’s Early Screening, Amyloid-β (Aβ), ApoA1 (Protein), ApoE (Protein), Aristotle University, B2M (Protein), BBC Health News, BDNF (Protein), Big Pharma, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Tests, Blood-Based Biomarkers, Brain Imaging, Brain Research, Case Finding, CathepsinD (Protein), Ceruloplasmin (Protein), CFH (Protein), CFH: Complement Factor H, Clinical Dementia Rating Scale, Clinical Trials and Treatment Assessments, Clusterin, Cognitive Impairment, Conversion to Dementia From Prodromal Disease, CRP: C-Reactive Protein, Dementia Case Finding, Dementia Consortium, Dementia Diagnosis, Dementia Innovation, Dementia Research, Dementia Screening, Department of Neurobiology Care Sciences and Society: Karolinska Institutet, Department of Neuroimaging Genetics: QIMR Berghofer Medical Research Institute, Department of Old Age Psychiatry: King's College London, Diagnosis, Diagnosis of Alzheimer's Disease, Diagnostic Imaging, Diagnostics, Disease-Modifying Therapies for Dementia, Drug Development for Alzheimer's Disease, Drug Discovery Programme, Drug Identification, Drug Trials Failure Rate, Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Differential Diagnosis, Early Screening, EMD Millipore Corporation, Exeter University, GlaxoSmithKline Medicines Research Centre, Global Clinical Development Fund, INSERM: University of Toulouse, Kings College London, Kuopio University Hospital, Magnetic Resonance Imaging (MRI), McGill Centre for Studies in Aging, MCI: Mild Cognitive Impairment, Mild Cognitive Impairment (MCI), MMSE: Mini-Mental State Examination, MRI Scans, NCAM (Protein), Non-Invasive Biomarkers, NSE (Protein), NSE: Neuron-Specific Enolase, Pharmaceutical Industry, Plasma Aβ Peptides, Plasma Proteins, Prealbumin (Protein), Preclinical Alzheimer's Disease, Preclinical Biomarkers in Alzheimer's Disease, Predictive Ability (of Tests), Prodromal Alzheimer's Disease, Proteome Sciences plc, QIMR Berghofer Medical Research Institute, RANTES (Protein), RANTES: Regulated on Activation Normal T Cell Expressed and Secreted, Rapid Screening, Recruitment Onto Dementia Clinical Trials, SAP (Protein), SAP: Serum Amyloid Protein, Screening, Screening for Dementia, Structural MRI, Translational Research, TTR: Transthyretin, University of Eastern Finland, University of Exeter Medical School: Exeter University, University of Oxford, University of Perugia, University of Toulouse, VCAM1 (Protein) | Leave a comment